GLIA Diagnostics

Our Team

The GLIA Team

GLIA Diagnostics brings together world-class expertise in clinical medicine, neuroscience, biomedical engineering, commercialisation, and manufacturing — united by a single purpose: delivering objective, rapid TBI diagnostics to the people who need them most.

A Multidisciplinary Team

Building a PoC molecular diagnostic platform requires deep expertise across multiple disciplines. The GLIA team combines decades of experience in emergency medicine, neurosurgery, biomedical R&D, IP, commercialisation, and manufacturing — supported by strategic partnerships across Australia and internationally.

Edmond Sorich

CEO

40 years of biomedical experience across R&D, research, translation and diagnostics, including senior management and operations.

R&D leadershipDiagnostics translationSenior management & operations
LinkedIn

Prof. Biswadev Mitra

Clinical Science Advisor

Head of Emergency Medicine Research, Alfred Hospital.

Emergency medicine researchClinical scienceAlfred Hospital

Prof. Jeffrey Rosenfeld

Clinical Advisor

Senior Neurosurgeon, Alfred Hospital. Prof. Surgery, Monash University. Brig. General/Surgeon General, ADF Reserves.

NeurosurgeryMilitary medicineMonash University & ADF

Dr. Lee Miles

IP Advisor

IP strategy and protection for GLIA’s miRNA biomarker portfolio and PoC diagnostic platform.

IPPatent strategyBiomedical IP

David Basseal

Commercialisation Advisor

Leadership positions including Roche, Becton Dickinson & Abbott.

CommercialisationRocheBecton Dickinson & Abbott

Milind Raje

Manufacturing Advisor

Manufacturing, Regulatory Engineering, Supply chain.

ManufacturingRegulatory engineeringSupply chain

Key Achievements

  • Multidisciplinary expertise spanning clinical medicine, diagnostics, regulatory development, commercialisation, manufacturing and emergency medicine.
  • Exclusive worldwide miRNA biomarker licence and GLIA-owned PoC intellectual property.
  • Five human studies and research cohorts.
  • Four peer-reviewed human publications.
  • ADF and US DoD research engagement.
  • International patent portfolio.
  • US professional football research collaboration.
  • NSW-based engineering and technology development partnerships.
  • A$1.5M+ cumulative non-dilutive support.
  • US$250K private pre-seed investment.

Key Stakeholders

  • The Alfred Hospital
  • CSIRO
  • ADF / US DoD
  • US professional football club
  • Macquarie University
  • Genesys Electronics Design
  • Memjet
  • North Shore AFL
  • NSW Rugby
  • American Football Australia

Join Us in Transforming TBI Diagnostics

We are actively seeking clinical collaborators, research partners, and strategic investors. If you share our commitment to objective brain injury diagnostics, we’d like to hear from you.